Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non Operating Income (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Other Non Operating Income for 4 consecutive years, with -$265.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income fell 3630.87% year-over-year to -$265.9 million, compared with a TTM value of -$133.7 million through Dec 2025, down 2254.24%, and an annual FY2025 reading of -$133.7 million, down 2254.24% over the prior year.
  • Other Non Operating Income was -$265.9 million for Q4 2025 at Zevra Therapeutics, down from $207000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $135.4 million in Q2 2025 and bottomed at -$265.9 million in Q4 2025.
  • Average Other Non Operating Income over 3 years is -$14.4 million, with a median of $361000.0 recorded in 2024.
  • Peak annual rise in Other Non Operating Income hit 7470.08% in 2025, while the deepest fall reached 3630.87% in 2025.
  • Year by year, Other Non Operating Income stood at $789000.0 in 2021, then surged by 854.5% to $7.5 million in 2024, then crashed by 3630.87% to -$265.9 million in 2025.
  • Business Quant data shows Other Non Operating Income for ZVRA at -$265.9 million in Q4 2025, $207000.0 in Q3 2025, and $135.4 million in Q2 2025.